+

WO2001051039A1 - Dispositif osmotique contenant du ranitidine et un agent procinetique - Google Patents

Dispositif osmotique contenant du ranitidine et un agent procinetique Download PDF

Info

Publication number
WO2001051039A1
WO2001051039A1 PCT/US2001/000610 US0100610W WO0151039A1 WO 2001051039 A1 WO2001051039 A1 WO 2001051039A1 US 0100610 W US0100610 W US 0100610W WO 0151039 A1 WO0151039 A1 WO 0151039A1
Authority
WO
WIPO (PCT)
Prior art keywords
osmotic device
ranitidine
osmotic
mammal
rnt
Prior art date
Application number
PCT/US2001/000610
Other languages
English (en)
Inventor
Joaquina Faour
Juan A. Vergez
Original Assignee
Osmotica Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Corp. filed Critical Osmotica Corp.
Priority to AU2001227744A priority Critical patent/AU2001227744A1/en
Publication of WO2001051039A1 publication Critical patent/WO2001051039A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • This invention pertains to an osmotic device containing ranitidine. More particularly, it pertains to an osmotic device tablet that provides a controlled release of ranitidine and a prokinetic agent, following a particularly advantageous release profile.
  • Gastroesophageal reflux disease (GERD), reflux esophagitis, peptic ulcer, gastric ulcer and other gastric acid related disorders are disorders having a pathogenesis related to reduced gastric motility, i.e., reduced clearing capacity of the stomach, and release of excessive gastric acid.
  • GERD and gastric ulcer have been successfully treated with a range of gastric acid inhibitors, such as ranitidine and omeprazole, which are known as H2 blocker or acid-suppressing drugs. Stimulation of gastric motility has been proposed to accelerate the healing of gastric ulcer.
  • Prokinetic drugs such as cisapride, are known to enhance gastrointestinal motility and prevent duodenogastric reflux, and are widely used to treat GERD.
  • Ranitidine and prokinetic drugs have been used in combination to treat gastric ulcer and other related disorders.
  • Ranitidine is commercially available in tablet, liquid and capsule dosage forms from Geneva Farms, Glaxo Wellcome (ZantacTM), Boehringer Ingelheim, Mylan, Novopharm NC, Ranbaxy, Torpharm, Wockhardt and Zenith Goldline.
  • the tablets and capsules are available in 150 and 300 mg strengths.
  • Osmotic devices and other tablet formulations are known for their ability to provide a controlled release of a wide range of drugs. Such osmotic devices and other tablet formulations are disclosed in U.S. Patent No. 4,014,334 to Theeuwes et al., U.S. Patent No. 4,576,604 to Guittard et al., Argentina Patent No. 234,493, U.S. Patent No.
  • the osmotic devices of the present invention seek to overcome the disadvantages found in known ranitidine formulations. These osmotic devices provide improved therapeutic benefits over conventional devices.
  • the present invention provides an osmotic device comprising: a core comprising a therapeutically effective amount of ranitidine and at least one osmotic agent or osmopolymer; and a semipermeable membrane surrounding the core and having a passageway there through; wherein the core provides a controlled release of RNT, and at least 60% of the RNT is released within 20 hours after exposure of the osmotic device to an aqueous solution.
  • an osmotic device for delivering ranitidine and a prokinetic agent comprising: a core comprising a therapeutically effective amount of ranitidine and at least one osmotic agent or osmopolymer; a semipermeable membrane surrounding the core and having a passageway there through; and an external coat comprising a therapeutically effective amount of a prokinetic agent and ranitidine; wherein the core provides a controlled release of RNT, and at least 60% of the RNT is released from the core within 20 hours after exposure of the osmotic device to an aqueous solution, and the external coat provides a rapid release of the prokinetic agent, and at least 75% of the prokinetic agent is released within 1 hour and 80% of RNT in the external coat is released within 1 hour after exposure of the osmotic device to an aqueous solution.
  • the external coat is applied by spray-coating or compression-coating.
  • spray coating rather than compression coating the external coat, a thinner external coat, and therefore a smaller osmotic device, is formed.
  • Another aspect of the invention provides a method of treating a gastric acid related disorder in a mammal.
  • This method comprises the step of administering an osmotic device, which provides a controlled release of RNT from its core and a rapid release of a prokinetic agent and RNT from an external coat and RNT, wherein at least 75% of the prokinetic agent is released within about 40 minutes, and at least about 75% of the RNT in the external coat is released within about 1 hour after administration.
  • Gastric acid-related disorders include, for example, gastric ulcer, peptic ulcer, GERD (gastroesophageal reflux disease), and reflux esophagitis.
  • the osmotic device provides: a) an RNT release profile similar to that shown in any of Figures 1-3; or b) an osmotic device made according to example 1.
  • the release of RNT and/or the prokinetic agent has a delayed onset.
  • the prokinetic agent is selected from the group consisting of cisapride, mosapride, domperidone and clevopride.
  • the osmotic device generally delivers the prokinetic agent to the upper GI tract and the ranitidine to the middle to lower GI tract.
  • the device can be tailored for once or twice daily administration.
  • the amounts of ranitidine and prokinetic agent can be varied.
  • One embodiment provides two different charges of ranitidine (one rapid release and the other controlled release) and a rapid release charge of prokinetic agent. This embodiment rapidly provides the therapeutic benefit of both drugs so that gastric discomfort is relieved shortly after administration.
  • FIG. 1 depicts an in vitro dissolution profile for RNT from the exemplary formulation of Example 1.
  • FIG. 2 depicts an in vitro dissolution profile for RNT from a second exemplary formulation.
  • FIG. 3 depicts an in vitro dissolution profile for RNT from a third exemplary formulation.
  • Ranitidine and prokinetic agents are available from large number of commercial sources such as Aldrich Chemical Co. or Sigma Chemical Co. or pharmaceutical manufacturers.
  • the invention provides for the administration of ranitidine alone or in combination with a prokinetic agent, wherein these compounds are in their free base, free acid, racemic, optically pure, diastereomeric and/or pharmaceutically acceptable salt forms.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the therapeutic compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the RNT or prokinetic agent.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfonic, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as amino acids, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • FIG. 1 depicts various ranitidine in vitro release profiles for the osmotic device tablets described in Example 1. This formulation exhibits a 24-hour or greater controlled release of RNT.
  • the RNT release profile of this exemplary 300 mg strength tablet formulation is generally described as follows:
  • FIG 2. depicts various RNT in vitro release profiles for 150 mg strength osmotic device tablets made according to a formulation similar to, but than, the formulation of Example 1.
  • This exemplary device provides a controlled release of RNT for a period of about 7 hours after administration.
  • the in vitro release profile can be generally characterized as follows:
  • FIG 3. depicts various RNT in vitro release profiles for 75 mg strength osmotic device tablets made according to a formulation similar to, but than, the formulation of Example 1.
  • This exemplary device provides a controlled release of RNT for a period of about 7 hours after administration.
  • the in vitro release profile can be generally characterized as follows:
  • All of the tablet formulations of the invention will provide therapeutically effective levels of ranitidine and a prokinetic agent for at least a predetermined period of time.
  • the tablets of the invention will generally provide therapeutically effective amounts of ranitidine for a period of not less than 18 hours and not more than 30 hours, preferably not less than 20 hours and not more than 28 hours, and more preferably not less than 22 hours and not more than 24 hours.
  • the tablets provide a controlled release of RNT for a period of about 5-10 hours and, preferably about 7 hours.
  • Specific embodiments of the method of the invention for treating gastric acid related disorders include those wherein: 1) the osmotic device releases ranitidine for a period of up to about 12 hours and is administered twice daily; 2) the osmotic device provides a therapeutic plasma level in the mammal for a period of up to about 12 hours; 3) the osmotic device releases ranitidine for a period of at least 18 hours and is administered once daily; 4) the osmotic device provides a therapeutic plasma level in the mammal for a period of up to about 24 hours; 5) the osmotic device delivers the prokinetic agent to the upper GI tract and the ranitidine to at least the upper and middle gastrointestinal tract of the mammal to which the device is administered orally; 6) the release of the RNT, the prokinetic agent or both has a delayed onset; 7) the prokinetic agent is selected from the group consisting of cisapride, mosapride, domperidone and clevopride; and/or 8) the
  • the osmotic device of the invention provides an improved therapeutic benefit over conventional devices containing only ranitidine or a prokinetic agent.
  • ranitidine and prokinetic agent according to the dissolution or release criteria described herein, an enhanced therapeutic result is obtained.
  • the external coating can be an immediately dissolving coating that dissolves in the buccal cavity or a rapidly dissolving coating that dissolved in the stomach, jejunum or duodenum.
  • the controlled release core generally begins to release ranitidine within about 2 hours after administration.
  • the rapid release coating will release all of its prokinetic agent, within three hours after administration, and preferably at least 75% of its prokinetic agent within about 40 minutes after administration.
  • ranitidine and prokinetic agent used in the osmotic device will vary according to, among other things, the desired pharmacokinetic behavior in a mammal.
  • the coat will generally comprise an inert and non-toxic material which is at least partially, and preferably substantially completely, soluble or erodible in an environment of use.
  • the rapidly dissolving coat will be soluble in the buccal cavity and/or upper GI tract, such as the stomach, duodenum, jejunum or upper small intestines. Exemplary materials are disclosed in U.S. Patents No.
  • the rapidly dissolving coat will be soluble in saliva, gastric juices, or acidic fluids.
  • the long acting controlled release tablet formulations that provide a delayed and sustained release of ranitidine may include an enteric coat which is soluble or erodible in intestinal juices, substantially pH neutral or basic fluids but for the most part insoluble in gastric juices or acidic fluids.
  • enteric coat which is soluble or erodible in intestinal juices, substantially pH neutral or basic fluids but for the most part insoluble in gastric juices or acidic fluids.
  • enteric coat which is soluble or erodible in intestinal juices, substantially pH neutral or basic fluids but for the most part insoluble in gastric juices or acidic fluids.
  • a wide variety of other polymeric materials are known to possess these various solubility properties.
  • Such other polymeric materials include, by way of example and without limitation, cellulose acetate phthalate (CAP), cellulose acetate trimelletate (CAT), poly(vinyl acetate) phthalate (PVAP), hydroxypropyl methylcellulose phthalate (HP), poly(methacrylate ethylacrylate) (1:1) copolymer (MA-EA), poly(methacrylate methylmethacrylate) (1:1) copolymer (MA-MMA), poly(methacrylate methylmethacrylate) (1:2) copolymer, Eudragit L-30-DTM (MA-EA, 1:1), EudragitTM L-100- 55TM (MA-EA, 1:1), hydroxypropyl methylcellulose acetate succinate (HPMCAS), CoatericTM (PVAP), AquatericTM (CAP), AQUACOATTM (HPMCAS) and combinations thereof.
  • CAP cellulose acetate phthalate
  • CAT cellulose acetate trimelletate
  • PVAP poly(
  • the enteric coat can also comprise dissolution aids, stability modifiers, and bioabsorption enhancers.
  • materials such as hydroxypropylcellulose, microcrystalline cellulose (MCC, AvicelTM from FMC Corp.), poly (ethylene - vinyl acetate) (60:40) copolymer (EVAC from Aldrich Chemical Co.), 2-hydroxyethylmethacrylate (HEMA), MMA, terpolymers of HEMA: MMA:MA synthesized in the presence of N,N'- bis(memacryloyloxyethyloxycarbonylamino) - azobenzene, azopolymers, enteric coated timed release system (Time Clock® from Pharmaceutical Profiles, Ltd., UK) and calcium pectinate can be used.
  • a preferred polymeric material for use in the enteric coat involves enteric materials that resist the action of gastric fluid avoiding permeation through the semipermeable wall while one or more of the materials in the core of the tablet are solubilized in the intestinal tract thereby allowing delivery of the ranitidine in the core by osmotic pumping in an osmotic device to begin.
  • a material that easily adapts to this kind of requirement is a poly(vinylpyrrolidone)-vinyl acetate copolymer, such as the material supplied by BASF under its Kollidon VA64 trademark, mixed with magnesium stearate and other similar excipients.
  • the enteric coat can also comprise povidone, which is supplied by BASF under its Kollidon K 30 trademark, and hydroxypropyl methylcellulose, which is supplied by Dow under its Methocel E-15 trademark.
  • the materials can be prepared in solutions of having different concentrations of polymer according to the desired solution viscosity. For example, a 10% P/N aqueous solution of Kollidon K 30 has a viscosity of about 5.5-8.5 cps at 20 °C, and a 2% P/N aqueous solution of Methocel E-15 has a viscosity of about 13- 18 cps at 20 °C.
  • the enteric coat can comprise one or more materials that do not dissolve, disintegrate, or change their structural integrity in the stomach and during the period of time that the tablet resides in the stomach.
  • Representative materials that keep their integrity in the stomach can comprise a member selected from the group consisting of (a) keratin, keratin sandarac-tolu, salol (phenyl salicylate), salol beta-naphthylbenzoate and acetotannin, salol with balsam of Peru, salol with tolu, salol with gum mastic, salol and stearic acid, and salol and shellac; (b) a member selected from the group consisting of formalized protein, formalized gelatin, and formalized cross-linked gelatin and exchange resins; (c) a member selected from the group consisting of myristic acid-hydrogenated castor oil-cholesterol, stearic acid-mutton tallow, stearic acid-balsam of to
  • an enteric composition comprising a member selected from the group consisting of cellulose acetyl phthalate, cellulose diacetyl phthalate, cellulose triacetyl phthalate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, sodium cellulose acetate phthalate, cellulose ester phthalate, cellulose ether phthalate, methylcellulose phthalate, cellulose ester-ether phthalate, hydroxypropyl cellulose phthalate, alkali salts of cellulose acetate phthalate, alkaline earth salts of cellulose acetate phthalate, calcium salt of cellulose acetate phthalate, ammonium salt of hydroxypropyl methylcellulose phthalate, cellulose acetate hexahydrophthalate, hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate diethyl phthalate, dibutyl phthalate, dialkyl phthalate,
  • the semipermeable membrane of the osmotic device is formed of a material that is substantially permeable to the passage of fluid from the environment of use to the core and substantially impermeable to the passage of active agent from the core.
  • a material that is substantially permeable to the passage of fluid from the environment of use to the core and substantially impermeable to the passage of active agent from the core.
  • Many common materials known by those of ordinary skill in the art are suitable for this purpose. Exemplary materials are cellulose esters, cellulose ethers and cellulose esters-ethers.
  • a semipermeable membrane consisting essentially of cellulose acetate (CA) and poly(ethylene gfycol) (PEG), in particular PEG 400, are preferred when used in combination with the other materials required in the present osmotic device.
  • CA cellulose acetate
  • PEG poly(ethylene gfycol)
  • This particular combination of CA and PEG provides a semipermeable membrane that gives the osmotic device a well controlled release profile for the active agent in the core and that retains its chemical and physical integrity in the environment of use.
  • the ratio of CA:PEG generally ranges from about 50-99% by weight of CA: about 50-1% by weight of PEG, and preferably about 95% by weight of CA: about 5% by weight of PEG. The ratio can be varied to alter permeability and ultimately the release profile of the osmotic device.
  • Other preferred materials can include a selected member of the group of cellulose acylates such as cellulose acetate, cellulose diacetate, cellulose triacetate and combinations thereof.
  • Many suitable polymers include those disclosed in Argentine Patent No. 199,301 and other references cited herein, the disclosures of which are hereby incorporated by reference.
  • the core of all the osmotic device tablet of the present invention will comprise ranitidine, at least one pharmaceutically acceptable excipient and optionally one or more other materials.
  • the tablet formulations will comprise about 0.1-99.9% by weight of ranitidine in the uncoated tablet core. Preferred ranges will vary according to prokinetic agent used and the intended use of the osmotic device.
  • the controlled release tablet is an osmotic device
  • osmotically effective solutes, osmotic agents or osmagents are added. These osmagents can aid in either the suspension or dissolution of the RNT in the core.
  • Exemplary osmagents include organic and inorganic compounds such as salts, acids, bases, chelating agents, sodium chloride, lithium chloride, magnesium chloride, magnesium sulfate, lithium sulfate, potassium chloride, sodium sulfite, calcium bicarbonate, sodium sulfate, calcium sulfate, calcium lactate, d-mannitol, urea, tartaric acid, raffinose, sucrose, alpha-d-lactose monohydrate, glucose, combinations thereof and other similar or equivalent materials which are widely known in the art. Osmagents can also be incorporated to the core of the osmotic device to control the release of RNT therefrom.
  • organic and inorganic compounds such as salts, acids, bases, chelating agents, sodium chloride, lithium chloride, magnesium chloride, magnesium sulfate, lithium sulfate, potassium chloride, sodium sulfite, calcium bicarbonate, sodium sulfate, calcium sulfate
  • the tablets of the invention can also comprise an acidifying agent, alkalizing agent, adsorbent, antioxidant, buffering agent, colorant, flavorant, sweetening agent, tablet antiadherent, tablet binder, tablet and capsule diluent, tablet direct compression excipient, tablet disintegrant, tablet glidant, tablet lubricant, tablet or capsule opaquant and/or tablet polishing agents.
  • the term "adsorbent” is intended to mean an agent capable of holding other molecules onto its surface by physical or chemical (chemisorption) means.
  • Such compounds include, by way of example and without limitation, powdered and activated charcoal and other materials known to one of ordinary skill in the art.
  • antioxidant is intended to mean an agent which inhibits oxidation and thus is used to prevent the deterioration of preparations by the oxidative process.
  • Such compounds include, by way of example and without limitation, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophophorous acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate and sodium metabisulfite and other materials known to one of ordinary skill in the art.
  • alkalizing agent is intended to mean a compound used to provide alkaline medium for product stability.
  • Such compounds include, by way of example and without limitation, ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine, and trolamine and others known to those of ordinary skill in the art.
  • the term "acidifying agent” is intended to mean a compound used to provide an acidic medium for product stability.
  • Such compounds include, by way of example and without limitation, acetic acid, amino acid, citric acid, fumaric acid and other alpha hydroxy acids, such as hydrochloric acid, ascorbic acid, and nitric acid and others known to those of ordinary skill in the art.
  • buffering agent is intended to mean a compound used to resist change in pH upon dilution or addition of acid or alkali.
  • Such compounds include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and sodium citrate anhydrous and dihydrate and other materials known to one of ordinary skill in the art.
  • sweetening agent is intended to mean a compound used to impart sweetness to a preparation.
  • Such compounds include, by way of example and without limitation, aspartame, dextrose, glycerin, mannitol, saccharin sodium, sorbitol and sucrose and other materials known to one of ordinary skill in the art.
  • tablette antiadherents is intended to mean agents which prevent the sticking of tablet formulation ingredients to punches and dies in a tableting machine during production.
  • tablettes include, by way of example and without limitation, magnesium stearate, talc, calcium stearate, glyceryl behenate, PEG, hydrogenated vegetable oil, mineral oil, stearic acid and other materials known to one of ordinary skill in the art.
  • tablette binders is intended to mean substances used to cause adhesion of powder particles in table granulations.
  • Such compounds include, by way of example and without limitation, acacia, alginic acid, carboxymethylcellulose sodium, poly(vinylpyrrolidone), compressible sugar (e.g., NuTab), ethylcellulose, gelatin, liquid glucose, methylcellulose, povidone and pregelatinized starch and other materials known to one of ordinary skill in the art.
  • binders may also be included in the tablets.
  • exemplary binders include acacia, tragacanth, gelatin, starch, cellulose materials such as methyl cellulose and sodium carboxy methyl cellulose, alginic acids and salts thereof, polyethylene glycol, guar gum, polysaccharide, bentonites, sugars, invert sugars, poloxamers (PLURONIC F68, PLURONIC F127), collagen, albumin, gelatin, cellulosics in nonaqueous solvents, combinations thereof and the like.
  • binders include, for example, polypropylene glycol, polyoxyethylene-polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, polyethylene oxide, combinations thereof and other materials known to one of ordinary skill in the art.
  • tablette diluent or “fillers” is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the preparation of tablets and capsules.
  • Such compounds include, by way of example and without limitation, dibasic calcium phosphate, kaolin, lactose, sucrose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, and starch and other materials known to one of ordinary skill in the art.
  • tablette direct compression excipient is intended to mean a compound used in direct compression tablet formulations.
  • Such compounds include, by way of example and without limitation, dibasic calcium phosphate (e.g., Ditab) and other materials known to one of ordinary skill in the art.
  • tablette glidant is intended to mean agents used in tablet and capsule formulations to reduce friction during tablet compression.
  • Such compounds include, by way of example and without limitation, colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, colloidal silicon, silicon hydrogel and other materials known to one of ordinary skill in the art.
  • tablette lubricant is intended to mean substances used in tablet formulations to reduce friction during tablet compression.
  • Such compounds include, by way of example and without limitation, calcium stearate, magnesium stearate, mineral oil, stearic acid, and zinc stearate and other materials known to one of ordinary skill in the art.
  • tablette/capsule opaquant is intended to mean a compound used to render a capsule or a tablet coating opaque. May be used alone or in combination with a colorant.
  • Such compounds include, by way of example and without limitation, titanium dioxide and other materials known to one of ordinary skill in the art.
  • tablette polishing agent is intended to mean a compound used to impart an attractive sheen to coated tablets.
  • Such compounds include, by way of example and without limitation, carnauba wax, and white wax and other materials known to one of ordinary skill in the art.
  • tablette disintegrant is intended to mean a compound used in solid dosage forms to promote the disruption of the solid mass into smaller particles which are more readily dispersed or dissolved.
  • exemplary disintegrants include, by way of example and without limitation, starches such as corn starch, potato starch, pre-gelatinized and modified starches thereof, sweeteners, clays, such as bentonite, microcrystalline cellulose(e.g., Avicel), carboxymethylcellulose calcium, cellulose polyacrilin potassium (e.g., Amberlite), alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pectin, tragacanth and other materials known to one of ordinary skill in the art.
  • starches such as corn starch, potato starch, pre-gelatinized and modified starches thereof, sweeteners, clays, such as bentonite, microcrystalline cellulose(e.g., Avicel), carboxymethylcellulose calcium, cellulose polyacrilin potassium (e.g.
  • colorant is intended to mean a compound used to impart color to solid (e.g., tablets) pharmaceutical preparations.
  • Such compounds include, by way of example and without limitation, FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, caramel, and ferric oxide, red, other F.D. & C. dyes and natural coloring agents such as grape skin extract, beet red powder, beta-carotene, annato, carmine, turmeric, paprika, and other materials known to one of ordinary skill in the art.
  • the amount of coloring agent used will vary as desired.
  • flavorant is intended to mean a compound used to impart a pleasant flavor and often odor to a pharmaceutical preparation.
  • exemplary flavoring agents or flavorants include synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may also include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oil of bitter almonds and cassia oil.
  • flavor examples include vanilla, citrus oil, including lemon, orange, grape, lime and grapefruit, and fruit essences, including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth.
  • Flavors that have been found to be particularly useful include commercially available orange, grape, cherry and bubble gum flavors and mixtures thereof. The amount of flavoring may depend on a number of factors, including the organoleptic effect desired. Flavors will be present in any amount as desired by those of ordinary skill in the art. Particularly preferred flavors are the grape and cherry flavors and citrus flavors such as orange.
  • the present tablets can also employ one or more commonly known surface active agents or cosolvents that improve wetting or disintegration of the tablet core or layers.
  • Plasticizers can also be included in the tablets to modify the properties and characteristics of the polymers used in the coats or core of the tablets.
  • the term "plasticizer” includes all compounds capable of plasticizing or softening a polymer or binder used in invention.
  • the plasticizer should be able to lower the melting temperature or glass transition temperature (softening point temperature) of the polymer or binder.
  • Plasticizers such as low molecular weight PEG, generally broaden the average molecular weight of a polymer in which they are included thereby lowering its glass transition temperature or softening point. Plasticizers also generally reduce the viscosity of a polymer. It is possible the plasticizer will impart some particularly advantageous physical properties to the osmotic device of the invention.
  • Plasticizers useful in the invention can include, by way of example and without limitation, low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene glycol), citrate ester-type plasticizers, triacetin, propylene glycol and glycerin.
  • plasticizers can also include ethylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, monopropylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, dibutylsebacate, acetyltributylcitrate, triethyl citrate, acetyl triethyl citrate, tributyl citrate and allyl glycolate.
  • plasticizers are commercially available from sources such as Aldrich or Sigma Chemical Co. It is also contemplated and within the scope of the invention, that a combination of plasticizers may be used in the present formulation.
  • the PEG based plasticizers are available commercially or can be made by a variety of methods, such as disclosed in Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications (J.M. Harris, Ed.; Plenum Press, NY) the disclosure of which is hereby incorporated by reference.
  • the tablets of the invention can also include oils, for example, fixed oils, such as peanut oil, sesame oil, cottonseed oil, corn oil and olive oil; fatty acids, such as oleic acid, stearic acid and isotearic acid; and fatty acid esters, such as ethyl oleate, isopropyl myristate, fatty acid glyceridees and acetylated fatty acid glycerides.
  • fixed oils such as peanut oil, sesame oil, cottonseed oil, corn oil and olive oil
  • fatty acids such as oleic acid, stearic acid and isotearic acid
  • fatty acid esters such as ethyl oleate, isopropyl myristate, fatty acid glyceridees and acetylated fatty acid glycerides.
  • Alcohols such as ethanol, isopropanol, hexadecyl alcohol, glycerol and propylene glycol; with glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol; with ethers, such as poly(ethyleneglycol) 450, with petroleum hydrocarbons, such as mineral oil and petrolatum; with water, or with mixtures thereof; with or without the addition of a pharmaceutically suitable surfactant, suspending agent or emulsifying agent.
  • alcohols such as ethanol, isopropanol, hexadecyl alcohol, glycerol and propylene glycol
  • glycerol ketals such as 2,2-dimethyl-l,3-dioxolane-4-methanol
  • ethers such as poly(ethyleneglycol) 450
  • petroleum hydrocarbons such as mineral oil and petrolatum
  • Soaps and synthetic detergents may be employed as surfactants and as vehicles for detergent compositions.
  • Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts.
  • Suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and all_ylamine acetates; anionic detergents, for example, alkyl, aryl and olefin sulfonates, alkyl, olefin, ether and monoglyceride sulfates, and sulfosuccinates; nonionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene)- ⁇ /oc/ -poly(oxypropylene) copolymers; and amphoteric detergents, for example, alkyl ⁇ -aminopropionates and 2- alkylimidazoline quaternary am
  • glycerylmonostearate nylon, cellulose acetate butyrate, d, 1- poly(lactic acid), 1,6 - hexanediamine, diethylene amine, starches, derivatized starches, acetylated monoglycerides, gelatin coacervates, poly (styrene - maleic acid) copolymer, glycowax, castor wax, stearyl alcohol, glycerol palmitostearate, poly(ethylene), poly(vinyl acetate), poly(vinyl chloride), 1,3 - butylene-glycoldimethacrylate, ethyleneglycol- dimethacrylate and methacrylate hydrogels.
  • a therapeutically effective amount is the amount or quantity of ranitidine which is sufficient to elicit the required or desired therapeutic response, or in other words, the amount which is sufficient to elicit an appreciable biological response when administered to a patient.
  • the tablets of the invention can assume any shape or form known in the art of pharmaceutical sciences.
  • the device of the invention can be a pill, sphere, tablet, bar, plate, paraboloid of revolution, ellipsoid of revolution or the like.
  • the tablets can also include surface markings, cuttings, grooves, letters and/or numerals for the purposes of decoration, identification and/or other purposes.
  • the tablets of the invention can be prepared according to the methods disclosed herein or those well known in the art, more specifically according to the methods disclosed in the disclosure incorporated herein by reference.
  • ranitidine and excipients that comprise the core are mixed in solid, semisolid or gelatinous form, then moistened and sieved through a specified screen to obtain uncoated cores.
  • the uncoated cores are then dried in a dryer and compressed, for example, by punching.
  • the compressed and uncoated cores are then covered with a semipermeable membrane.
  • the semipermeable membrane surrounding the core should be perforated with, for example, laser equipment.
  • an external coat containing the prokinetic agent is applied to the semipermeable membrane.
  • the external coat can be applied as a compression-coating, but it is preferably applied as a spray-on coating.
  • the sprayed-on coating is thinner and lighter than the compression coating, and an osmotic device including the sprayed on external coating is, therefore, smaller than a similar osmotic device having a compression coat.
  • a smaller size osmotic device generally results in increased patient compliance in taking the osmotic device and is therefore advantageous.
  • the tablets of the invention can be coated with a finish coat as is commonly done in the art to provide the desired shine, color, taste or other aesthetic characteristics.
  • Materials suitable for preparing the finish coat are well known in the art and found in the disclosures of many of the references cited and incorporated by reference herein.
  • ranitidine HC1 350+35 mg strength
  • cisapride monohydrate (10+5 mg) strength tablets was prepared by mixing 292.95 g of ranitidine HC1, 68.05 g of microcrystalline cellulose, 50.00 g of povidone, 3.50 g of colloidal silicon dioxide. The mixture was blended to homogenize; then, 4.50 g of magnesium stearate was added as lubricant. This blend was tabletted to 800 mg - 1000 mg/core and hardness of 8 - 12 kp with flat faced, 13.0-mm diameter punches.
  • the slugs were milled by passing through a standard USP 20-mesh screen and were blended with 3.50 g of colloidal silicon dioxide and 4.50 g of magnesium stearate. The final blend was tabletted using biconcaves, 10 mm diameter punches. Cores weight: 407 mg Hardness from 15 to 20 kp.
  • a first composition (for the semipermeable membrane) to cover the cores was prepared as follows: 47.79 g of cellulose acetate and 2.52 g of polyethylene glycol 400 in a mixture of methylene chloride-methyl alcohol 70:30 v/v (volume/volume). This polymer mixture was sprayed onto the cores in a conventional pan coater to obtain film-coated tablets whose membrane coating weighed 50.4 mg approximately.
  • a 0.50-mm hole was drilled through the coating in one face of the tablet.
  • a second composition (for the inert water soluble coating) to cover the film-coated tablets was prepared as follows: 3.90 g of copolyvidone, 3.50 g of titanium dioxide, 0.10 g of Aluminum Lake Brilliant Blue and 12.50 g of talc were mixed in isopropyl alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets whose membrane coating weighed 20 mg approximately.
  • a third coating (for the water soluble drug-containing coating) was prepared by mixing 55.80 g of ranitidine HC1, 10.39 g of cisapride monohydrate, 200.00 g of microcrystalline cellulose and 1.50 g of colloidal silicon dioxide.
  • the mixture was blended to homogenize; then, 4.00 g of magnesium stearate was added as lubricant.
  • This blend was tabletted to 800-1000 mg/core and hardness of 8-12 kp with 13.0-mm diameter flat faced punches.
  • the slugs were milled by passing through a standard USP 20-mesh screen and were blended with 211.31 g of microcrystalline cellulose, 10.0 g of crospovidone, 1.5 g of colloidal silicon dioxide and 5.5 g of magnesium stearate.
  • This final blend was tabletted using 14-mm diameter biconcaves punches, surrounding the previous film-coated tablets which layer coating weighed 500.3 mg. Hardness: 14-18 kp.
  • a fourth composition (for the inert water soluble coating) to cover the previous tablets was prepared as follows: 18.18 g of hydroxypropyl methylcellulose 2910, 5.18 g of polyethylene glycol 6000 and 6.64 g of titanium dioxide were mixed in a mixture of methylene chloride-alcohol 96°. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane weighed 30 mg approximately.
  • Tablets made according to the above describe procedure generally had a formulation as follows:
  • ranitidine HCl (175 ⁇ 20 mg strength) and cisapride monohydrate (10 ⁇ 5 mg strength) tablets was prepared by mixing 140.62 g. of ranitidine HCl, 60.83 g of microcrystalline cellulose, 16.95 g of povidone, 2.80 g of colloidal silicon dioxide. The mixture was blended to homogeneity. Then, 3.0 g of magnesium stearate was added as lubricant. This blend was tabletted to 800-1000 mg/core and hardness of 8-12 kp with 13.0-mm diameter flat faced punches.
  • a first composition (for the semipermeable membrane) to cover the cores was prepared as follows: 15.20 g of cellulose acetate and 1.60 g of polyethylene glycol 400 in a mixture of methylene chloride-methyl alcohol 70:30 v/v (volume/volume). This polymer mixture was sprayed onto the cores in a conventional pan coater to obtain film-coated tablets which membrane weighed 16.80 mg approximately. A 0.50 mm-hole was drilled trough the coating on one face of the tablet.
  • a second composition (for the inert water soluble coating) to cover the film-coated tablet was prepared as follows: 3.12 g of copolyvidone, 2.80 g of titanium dioxide, 0.080 g of Aluminium Lake Red Ponceau and 10.0 g of talc were mixed in isopropyl alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film- coated tablets which membrane weighed 16.0 mg approximately.
  • a third coating (for the water soluble drug-containing coating) was prepared by mixing 33.48 g of ranitidine HCl, 10.39 g of cisapride monohydrato and 150.0 g of microcrystalline cellulose. The mixture was blended to homogenize; then, 2.75 g of magnesium stearate was added as lubricant. This blend was tabletted to 800-1000 mg/core and hardness of 8-12 kp with 13.0-mm diameter flat faced punches. The slugs were milled by passing through a standard USP 20-mesh screen and were blended with 2.75 g of magnesium stearate. This final blend was tabletted using 12-mm diameter biconcaves punches, surrounding the previous film-coated tablets whose layer coating weighed 362 mg. Hardness: 10-15 kp.
  • a fourth composition (for the inert water soluble coating) to cover the previous tablets was prepared as follows: 10.89 g of hydroxypropyl methylcellulose 2910, 3.1 g of polyethylene glycol 6000 and 4.01 g of titanium dioxide were mixed in a mixture of methylene chloride-alcohol 96°. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets whose membrane weighed 18 mg approximately.
  • Polyethylene Glycol 400 1.600 mg.
  • Cisapride Monohydrate 10.390 mg.
  • Titanium Dioxide 4.010 mg.
  • This exemplary formulation provided a release profile similar to that of FIG. 2.
  • ranitidine HCl 85+10 mg strength
  • cisapride monohydrate 10 ⁇ 5 mg strength
  • the mixture was blended to homogenize; then, 0.55 g of magnesium stearate was added as lubricant. This blend was tabletted to 800-1000 mg/core and hardness of 8-12 kp with 13.0-mm diameter flat faced punches.
  • the slugs were milled by passing through a standard USP 20-mesh screen and were blended with 0.19 g of colloidal silicon dioxide and 0.55 g of magnesium stearate. The final blend was tabletted using 6.50-mm diameter biconcave punches. Cores weight: 105 mg. Hardness: 10-14 kp.
  • a first composition (for the semipermeable membrane) to cover the cores was prepared as follows: 12.13 g of cellulose acetate and 1.27 g of polyethylene glycol 400 in a mixture of methylene chloride-methyl alcohol 70:30 v/v (volume/volume). This polymer mixture was sprayed onto the cores in a conventional pan coater to obtain film-coated tablets which membrane weighed approximately 13.40 mg. A 0.50 mm-hole was drilled trough the coating in one face of the tablet.
  • a second composition (for the inert water soluble coating) to cover the film-coated tablet was prepared as follows: 2.61 g of copolyvidone, 2.35 g of titanium dioxide, 0.070 g of Aluminum Lake Red Ponceau and 8.38 g of talc were mixed in isopropyl alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film- coated tablets which membrane weighed approximately 13.40 mg.
  • a third coating (for the water soluble drug-containing coating) was prepared by mixing 22.32 g of ranitidine HCl, 10.39 g of cisapride monohydrate and 100.0 g of microcrystalline cellulose. The mixture was blended to homogeneity; then, 2.0 g of magnesium stearate was added as lubricant. This blend was tabletted to 800-1000 mg/core and hardness of 8-12 kp with, 13.0-mm diameter flat faced punches. The slugs were milled by passing through a standard USP 20-mesh screen and were blended with 1.35 g of colloidal silicon dioxide, 4.21 g of crospovidone and 2.0 g of magnesium stearate.
  • This final blend was tabletted using 12-mm diameter biconcave punches, surrounding the previous film-coated tablets which layer coating weighed 250.0 mg. Hardness: 10-14 kp.
  • a fourth composition (for the inert water soluble coating) to cover the previous tablets was prepared as follows: 7.26 g of hydroxypropyl methylcellulose 2910, 2.07 g of polyethylene glycol 6000 and 2.67 g of titanium dioxide were mixed in a mixture of methylene chloride-alcohol 96°. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane weighed 12 mg approximately. Tablets made according to the above-described procedure generally included the following ingredients in the approximate amounts indicated.
  • Polyethylene Glycol 400 1.270 mg.
  • Copolyvidone 2.610 mg.
  • Cisapride Monohydrate 10.390 mg.
  • Titanium Dioxide 2.67 0 mg.
  • This exemplary formulation provided a release profile similar to that of FIG. 3.
  • EXAMPLE 4 An osmotic device according to the invention was prepared according to Example 1 and generally containing the following ingredients in the approximate amounts indicated.
  • Cellulose Acetate (Cellulose ester) 10.50 - 19.20 mg
  • Copolyvidone (Water soluble polymer) 1.50 - 3.50 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un dispositif osmotique contenant du ranitidine à diffusion contrôlée dans le noyau associé à un agent procinétique dans une couverture externe de diffusion rapide. Une large gamme d'agents procinétiques peut servir dans ce dispositif. Certains modes de réalisation de la présente invention proposent des dispositifs osmotiques dotés de profils de diffusion prédéterminés. L'un des modes de réalisation du dispositif osmotique comprend une couverture externe déposée par pulvérisation plutôt que par compression sur le dispositif. Le dispositif avec son noyau externe recouvert par pulvérisation est plus petit et aussi plus facile à avaler que le dispositif similaire présentant une couverture externe obtenue par compression. Ce dispositif sert à traiter les troubles associés à l'acide gastrique. Ce dispositif peut être adapté à une prise quotidienne ou biquotidienne. On peut faire varier les quantités de ranitidine et d'agent procinétique. Selon un mode de réalisation, deux charges différentes de ranitidine (l'une rapide, l'autre à diffusion contrôlée) et une charge à diffusion rapide d'agent procinétique sont proposées.
PCT/US2001/000610 2000-01-13 2001-01-09 Dispositif osmotique contenant du ranitidine et un agent procinetique WO2001051039A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001227744A AU2001227744A1 (en) 2000-01-13 2001-01-09 Osmotic device containing ranitidine and a prokinetic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17584400P 2000-01-13 2000-01-13
US60/175,844 2000-01-13

Publications (1)

Publication Number Publication Date
WO2001051039A1 true WO2001051039A1 (fr) 2001-07-19

Family

ID=22641875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000610 WO2001051039A1 (fr) 2000-01-13 2001-01-09 Dispositif osmotique contenant du ranitidine et un agent procinetique

Country Status (4)

Country Link
AR (1) AR026837A1 (fr)
AU (1) AU2001227744A1 (fr)
UY (1) UY26537A1 (fr)
WO (1) WO2001051039A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162777A1 (fr) * 2011-06-03 2012-12-06 Eurofarma Laboratórios S.A Composition pharmaceutique orale comprenant un inhibiteur de la pompe à protons et un agent prokinétique, à utiliser en cas de troubles liés à l'excès d'acide gastrique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162777A1 (fr) * 2011-06-03 2012-12-06 Eurofarma Laboratórios S.A Composition pharmaceutique orale comprenant un inhibiteur de la pompe à protons et un agent prokinétique, à utiliser en cas de troubles liés à l'excès d'acide gastrique

Also Published As

Publication number Publication date
AU2001227744A1 (en) 2001-07-24
AR026837A1 (es) 2003-02-26
UY26537A1 (es) 2001-07-31

Similar Documents

Publication Publication Date Title
US6605302B2 (en) Drug delivery device containing oseltamivir and an H1 antagonist
CA2396156C (fr) Dispositif osmotique contenant de la venlafaxine et un agent antipsychotique
EP1246612B1 (fr) Dispositif osmotique contenant de la pseudoephedrine et de la fexofenadine
US6569456B2 (en) Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6599532B2 (en) Osmotic device containing alprazolam and an antipsychotic agent
US6248359B1 (en) Multi-tablet oxybutynin system for treating incontinence
US6521255B2 (en) Osmotic device containing ranitidine and a prokinetic agent
US8252331B2 (en) Osmotic device containing amantadine and an osmotic salt
AU2005328058B2 (en) Osmotic device containing amantadine and an osmotic salt
EP1714641B1 (fr) Dispositif osmotique contenant un sel de venlavaxine et un sel possedant un ion en commun
US7147870B2 (en) Osmotic device containing pseudoephedrine and an H1 antagonist
US20050129764A1 (en) Osmotic device containing licofelone
WO2001051039A1 (fr) Dispositif osmotique contenant du ranitidine et un agent procinetique
CA2614647C (fr) Dispositif osmotique contenant de la venlafaxine et un agent antipsychotique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载